ArticleWorld journal of urology2026
Comment on "Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data".
Zhipeng Fan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.